MicroTech Medical (Hangzhou) Co (2235) Fair Value & Analysis
Healthcare · HK · Market cap HK$3.0B
Fair value as of: Aug 5, 2026
From 15 valuation models · updated 5 days ago
Fair value updated Aug 5, 2026, revised from HK$3.84 to HK$3.82 (−0.5%) since Jul 2, 2026. Share price −3.7% over the past month.
A solid business, but screening 45% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$3.82). The favourable scenario is already priced in.
- Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (HK$3.78 to HK$3.82), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 5, 2026.
How to read this chart
58‑month range HK$3.56 – HK$30.75 · fair‑value band HK$3.78 – HK$3.82 · the HK$6.98 price screens above the HK$3.82 fair value. Dashed = 300-day average. As of Aug 5, 2026.
Analysis
MicroTech Medical (Hangzhou) Co (2235) currently trades at HK$6.98, while our model-based Fair Value estimate is HK$3.82, implying the stock looks roughly 45.3% overvalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, MicroTech Medical (Hangzhou) Co generated revenue of HK$661M at a net margin of 6.1%. Revenue grew 113.0% year over year. It earns a return on equity of 2.0%. The balance sheet holds a net cash position of HK$1.4B. Fundamentals as of Aug 5, 2026
Our scenario range runs from HK$3.78 (bear case) to HK$3.82 (bull case); at HK$6.98, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -45%, 2235 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (HK$5.03) versus Multiples (HK$2.20). Highest evidence: Residual Income (76).
Notify me when 2235 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring and treatment medical devices in China and internationally.
Full company description
MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring and treatment medical devices in China and internationally. The company offers Equil patch insulin pump systems; AiDEX and LinX continuous glucose monitoring systems; POCT analyzer systems; closed-loop artificial pancreas systems; blood glucose monitoring systems; Exactive Pro blood glucose, blood ketone, and uric acid monitoring system; API open platform; and diabetes digital management software. It also involved in scientific research and technical services; business services; wholesale and retail; manufacturing; and commercials business. MicroTech Medical (Hangzhou) Co., Ltd. was incorporated in 2011 and is headquartered in Hangzhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MicroTech Medical (Hangzhou) Co reported revenue of HK$661M in FY2025 versus HK$151M in FY2021, a compound +44.5%/yr. Reported net income was HK$40.2M in FY2025.
2235 screens 45% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare MicroTech Medical (Hangzhou) Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MicroTech Medical (Hangzhou) Co (2235) overvalued or undervalued?
What is the fair value of 2235?
What is the quality score of 2235?
What is the revenue of MicroTech Medical (Hangzhou) Co (2235)?
What is the net profit margin of 2235?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MicroTech Medical (Hangzhou) Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.